Arrowhead Pharmaceuticals Inc (ARWR)
24.66
+1.71
(+7.45%)
USD |
NASDAQ |
Jun 03, 16:00
24.66
0.00 (0.00%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Cash from Financing (Quarterly): 430.78M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 430.78M |
December 31, 2023 | 0.267M |
September 30, 2023 | 0.152M |
June 30, 2023 | 1.805M |
March 31, 2023 | 0.52M |
December 31, 2022 | 250.58M |
September 30, 2022 | 0.855M |
June 30, 2022 | 60.60M |
March 31, 2022 | 1.846M |
December 31, 2021 | 1.885M |
September 30, 2021 | 0.815M |
June 30, 2021 | 2.755M |
March 31, 2021 | 2.633M |
December 31, 2020 | 5.102M |
September 30, 2020 | 1.005M |
June 30, 2020 | 2.132M |
March 31, 2020 | 1.333M |
December 31, 2019 | 253.48M |
September 30, 2019 | 1.833M |
June 30, 2019 | 2.767M |
March 31, 2019 | 2.67M |
December 31, 2018 | 59.11M |
September 30, 2018 | 1.571M |
June 30, 2018 | 1.454M |
March 31, 2018 | 56.90M |
Date | Value |
---|---|
December 31, 2017 | 0.0263M |
September 30, 2017 | -0.1223M |
June 30, 2017 | 0.00 |
March 31, 2017 | 0.1421M |
December 31, 2016 | 12.04M |
September 30, 2016 | 53.64M |
June 30, 2016 | 2.205M |
March 31, 2016 | -0.2224M |
December 31, 2015 | -0.4946M |
September 30, 2015 | 0.1369M |
June 30, 2015 | -0.0535M |
March 31, 2015 | 0.0268M |
December 31, 2014 | 0.1803M |
September 30, 2014 | 0.5358M |
June 30, 2014 | 4.342M |
March 31, 2014 | 117.65M |
December 31, 2013 | 62.77M |
September 30, 2013 | 2.003M |
June 30, 2013 | 35.31M |
March 31, 2013 | 3.703M |
December 31, 2012 | 3.279M |
September 30, 2012 | 5.504M |
June 30, 2012 | 2.653M |
March 31, 2012 | 1.181M |
December 31, 2011 | 1.432M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.152M
Minimum
Sep 2023
430.78M
Maximum
Mar 2024
51.16M
Average
1.866M
Median
Cash from Financing (Quarterly) Benchmarks
Viking Therapeutics Inc | 606.04M |
Madrigal Pharmaceuticals Inc | 573.71M |
89bio Inc | 21.03M |
Akero Therapeutics Inc | 366.94M |
Sagimet Biosciences Inc | 104.85M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -92.38M |
Cash from Investing (Quarterly) | -268.94M |
Free Cash Flow | -470.16M |
Free Cash Flow Per Share (Quarterly) | -1.026 |
Free Cash Flow Yield | -17.14% |